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Abstract
Background
HIV	infection	and	substance	use	synergistically	impact	health	outcomes	of	people	with	HIV.	In	this	study,	we	assessed	the	prevalence	of	substance	use	among	women	living	with	HIV	(WLWH)	and	compared	them	with
expected	values	from	general	data.
Methods
Cigarette	smoking,	frequency	of	alcohol	consumption,	last-month	non-prescribed	cannabis	use	(vs.	last-year	use),	and	last	3	months	regular	(≥once/week)	and	occasional	(-–
2015	Canadian	HIV	Women’s	Sexual	and	Reproductive	Health	Cohort	Study	(CHIWOS;	N = 1422)	and	compared	with	general	population	women	from	the	2013-–2014	Canadian	Community	Health	Survey
(CCHS;	N = 46,831).	Age/ethnoracial-standardized	prevalence	differences	(SPD)	and	95%	confidence	intervals	(CI)	were	reported.
1	Introduction
Substance	use	is	a	common	health	risk	behavior	among	people	living	with	HIV	(PLWH),	who	have	a	demonstrated	greater	prevalence	than	their	general	population	counterparts	(Ikeda	et	al.,	2016;	Mdodo	et	al.,	2015;	Tron	et
al.,	2014).	Substance	use	is	considered	a	major	barrier	to	successful	HIV	care	and	treatment	(Cofrancesco	et	al.,	2008;	Cook	et	al.,	2009;	Durvasula	and	Miller,	2014;	Gonzalez	et	al.,	2011;	Hicks	et	al.,	2007;	Malta	et	al.,	2008)	despite
the	substantial	advances	obtained	from	combination	antiretroviral	therapy	(cART),	e.g.,	improved	life	expectancy	in	PLWH	(Antiretroviral	Therapy	Cohort	Collaboration,	200 (Here	is	the	reference	that	looked	like	being	missed	but	it	should
be	actually	cited	here	as:	(Antiretroviral	Therapy	Cohort	Collaboration,	2008))8).	Substance	use	independently	or	by	interaction	with	other	factors	such	as	psychiatric	disorders	and	socioeconomic	marginalization	has	the	potential	to	limit	the
remarkable	benefits	of	cART	and	pose	additional	barriers	to	HIV	prevention	efforts	and	medical	care	(Durvasula	and	Miller,	2014;	Feldman	et	al.,	2006;	Gonzalez-Serna	et	al.,	2014;	Gonzalez	et	al.,	2011;	Hicks	et	al.,	2007;	Malta	et	al.,
2008;	Petoumenos	and	Law,	2016;	Vagenas	et	al.,	2015).
Previous	studies	have	reported	the	negative	impacts	of	tobacco	smoking	(Feldman	et	al.,	2006),	problematic	alcohol	consumption	(Vagenas	et	al.,	2015),	and	illicit	drug	use	(e.g.,	heroin)	(Cofrancesco	et	al.,	2008;	Hicks	et	al.,
2007)	on	HIV	care	cascade	outcomes	such	as	cART	non-adherence.	The	optimal	levels	of	these	outcomes	are	critical	in	promoting	the	health	of	PLWH	and	maintaining	treatment	as	prevention	(TasP)	targets	(Cohen	et	al.,	2016).	Beyond
its	interruption	of	care	and	treatment,	substance	use	can	also	interfere	with	cART	metabolism	and	virological	response	(Barve	et	al.,	2010;	Kumar	et	al.,	2015),	and	contribute	to	excess	mortality	(Feldman	et	al.,	2006;	Helleberg	et	al.,
2015).	For	example,	in	a	study	of	17,995	PLWH	on	treatment,	smoking	increased	the	rate	of	death	by	1.94	times,	with	1.84	and	2.41	times	in	men	and	women	with	HIV,	respectively	(Helleberg	et	al.,	2015).
Substance	use	vulnerability	appears	to	have	greater	 impacts	on	HIV	and	clinical	outcomes	among	women	than	men	with	HIV.	For	example,	women	with	 injection	drug	use	(IDU)	history	and	Indigenous	ancestry	had	lower
optimal	adherence	to	treatment	(47.8%)	relative	to	their	male	HIV-positive	counterparts	with	(57.7%)	and	without	(83.8%)	such	vulnerabilities	(Puskas	et	al.,	2017).	Women	with	IDU	history	were	also	found	to	be	18%	less	likely	to
achieve	HIV	RNA	viral	suppression	than	their	male	counterparts	(Cescon	et	al.,	2013).	Other	than	the	unique	experiences	of	HIV	infection	among	women	(e.g.,	pregnancy),	drug	use	along	with	greater	experiences	of	other	psychosocial,
economic	and	structural	challenges	may	account	for	gender-related	differences	in	HIV	outcomes	(Cescon	et	al.,	2013;	Kuyper	et	al.,	2004;	Wood	et	al.,	2008).
However,	substance	use	prevalence	among	women	living	with	HIV	(WLWH)	has	not	been	well-characterized,	particularly	in	Canada.	Population-based	research	has	either	overlooked	collecting	data	on	WLWH	or	has	not	had	the
adequate	sample	size	to	provide	estimates	for	WLWH	and	comparisons	to	the	broader	population	(Loutfy	et	al.,	2013;	Webster	et	al.,	2018).	Women	now	constitute	more	than	half	of	all	individuals	living	with	HIV	worldwide	(UNAIDS,
2014)	and	represent	nearly	one-fourth	of	the	estimated	75,500	PLWH	in	Canada;	almost	doubled	from	the	1990s	(Public	Health	Agency	of	Canada,	2015).	Understanding	the	prevalence	of	substance	use	in	a	geographically	diverse
sample	of	WLWH	relative	to	general	population	women	is	important	because	of	the	profound	implications	for	HIV	management	and	to	assess	the	need	for	harm	reduction	and	socio-structural	supports	for	women	who	use	substances.
Therefore,	 the	 objective	 of	 this	 research	 was	 to	 characterize	 the	 prevalence	 of	 cigarette	 smoking,	 alcohol	 consumption,	 non-prescribed	 cannabis	 use,	 and	 illicit	 drug	 use	 from	 the	 Canadian	 HIV	 Women’s	 Sexual	 and
Reproductive	Cohort	Study	 (CHIWOS),	a	 large	community-based	research	of	WLWH	in	Canada.	We	estimated	 the	prevalence	 for	substance	use	 in	CHIWOS	and	compared	 them	with	data	 from	HIV-negative	women	of	 the	general
population,	standardized	to	the	age/ethnoracial	distribution	of	WLWH.	Our	aim	was	to	document	substance	use	disparities	between	WLWH,	to	explore	differences	based	on	HIV	status	and	to	identify	needs	with	regard	to	resource
allocation,	particularly	given	the	implications	of	substance	use	in	the	context	of	HIV-related	medical	care.
2	Methods
2.1	Participants
Results
Compared	to	expected	estimates	from	general	population	women,	a	higher	proportion	of	WLWH	reported	daily	cigarette	smoking	(SPD:	26.8%	[95%	CI:	23.9,	29.7]),	smoking	≥20	cigarettes/day	(SPD:	11.6%	[9.8,	13.6]),
regular	non-prescribed	cannabis	use	(SPD:	8.0%	[4.1,	8.6]),	regular	crack/cocaine	use	(SPD:	16.7%	[13.1,	20.9]),	regular/occasional	speed	use	(SPD:	2.4%	[1.2,	4.7]),	and	heroin	use	(SPD:	11.2%	[8.3,	15.0]).	However,	WLWH
reported	lower	frequencies	of	alcohol	consumption	and	binge	drinking	than	their	counterparts	in	the	general	population.
Conclusions
Cigarette	smoking	and	illicit	drug	use,	but	not	alcohol	use	or	binge	drinking,	were	more	prevalent	in	WLWH	than	would	be	expected	for	Canadian	women	with	a	similar	age	and	ethnoracial	group	profile.	These	findings
may	indicate	the	need	for	women-centered	harm	reduction	programs	to	improve	health	outcomes	of	WLWH	in	Canada.
Keywords:	Women;	HIV;	CHIWOS;	Substance	use;	General	population;	Canada
2.1.1	CHIWOS	Ssample
We	used	data	 from	the	baseline	survey	of	 the	Canadian	HIV	Women’s	Sexual	and	Reproductive	Health	Cohort	Study	 (CHIWOS)	conducted	between	2013	and	2015.	CHIWOS	 is	a	 large	community-based	research	of	WLWH	(≥16	years;	 trans-
inclusive:	3.8%),	residing	in	British	Columbia	(BC),	Ontario,	and	Quebec.	Study	design	and	sampling	procedure	were	published	elsewhere	(Loutfy	et	al.,	2017).	Briefly,	applying	the	Meaningful	Involvement	of	Women	Living	with	HIV/AIDS	(MIWA)	principle,
reflecting	the	recognition	of	the	rights	and	responsibilities	of	individuals	living	with	HIV	as	equal	partners	to	actively	engage	throughout	the	design	and	delivery	of	HIV/AIDS	services	to	strengthen	the	responses	to	HIV/AIDS	epidemics	(UNAIDS,	2007).	A
sample	of	1422	WLWH	was	recruited	from	HIV	clinics,	AIDS	Service	Organizations,	peers,	and	online	networks	(Webster	et	al.,	2018).	The	survey	was	administered	by	Peer	Research	Associates	(PRAs),	many	of	whom	also	shared	the	experience	of	living
with	HIV	were	hired	and	trained	in	community-based	research	conduction	(Loutfy	et	al.,	2017).	The	averaged	120-minute-long	surveys	were	administered	either	through	in-person	interviews	at	the	clinic,	community	sites,	at	the	participants’	homes	or	via
phone/Skype.	CHIWOS	was	approved	by	the	Research	Ethics	Boards	of	Simon	Fraser	University,	University	of	British	Columbia/Providence	Health,	Women’s	College	Hospital	and	McGill	University	Health	Centre.
2.1.2	CCHS	Ssample
We	used	data	from	the	2013-–2014	cycle	of	the	Canadian	Community	Health	Survey	(CCHS),	a	nation-wide	cross-sectional	survey	administered	by	Statistics	Canada.	Detailed	documentation	is	available	elsewhere	(Canadian	Community	Health
Survey,	2013).	Briefly,	CCHS	is	designed	to	provide	nationally	representative	estimates	on	health	status,	health	care	utilization,	and	health	determinants	of	Canadians	aged	12	years	or	older	residing	in	private	dwellings	of	all	provinces	and	territories
(~98%	coverage),	excluding	populations	 living	on	reserves/Indigenous	settlements,	 institutions,	Canadian	Force	Bases,	and	some	remote	regions.	Data	are	collected	using	computer-assisted	personal	and	 telephone	 interview	software.	Consistent	with
CHIWOS,	CCHS	analyses	were	restricted	to	women	aged	≥16	years	old,	residing	in	the	three	provinces	(analytic	sample = 46,851).	Measures	of	cigarette	smoking,	alcohol	consumption,	non-prescribed	cannabis	use	and	illicit	drug	use	with	similar	content
and	wording	were	compared	between	the	two	surveys.
2.2	Measures
Although	cigarette	smoking	and	alcohol	consumption	were	collected	from	all	CCHS	respondents,	measures	of	drug	use	were	not	collected	in	Ontario	and	Quebec;	for	comparability,	we	provided	estimates	of	drug	use	for	only
BC	in	CHIWOS.
2.2.1	Cigarette	Ssmoking
In	CHIWOS,	cigarette	smoking	history	was	measured	as,	“What	is	your	cigarette	(tobacco)	smoking	history?”	with	four	response	options	(regular,	occasional,	former,	and	never).	In	CCHS,	the	same	question	was	asked	with	three	response	options
(daily,	occasionally,	not	at	all).	To	be	consistent	with	the	CCHS	definition,	we	categorized	WLWH	who	reported	at	least	one	cigarette/day	(equivalently,	at	least	30	cigarettes/month)	as	“daily”	smokers	irrespective	of	how	they	were	self-identified.	As	such,	67
self-identified	occasional	smokers	were	re-coded	as	daily	smokers,	and	two	cases	who	reported	cigarette	smoking	regularly	were	re-coded	as	occasional	smokers.	Two	measures	were	created	to	compare	the	two	surveys:	a)	nonsmokers	at	the	time	of
interview	(i.e.,	former	or	none)	versus	current	smokers	(i.e.,	daily	or	occasional),	and	b)	a	three-category	measure:	nonsmokers,	occasional	smokers,	and	daily	smokers.	We	also	reported	cigarette	smoking	intensity/quantity	among	current	smokers.	A	five-
category	measure	was	created	to	compare	the	two	surveys:	nonsmokers	(former	or	never),	<1	cigarette/day	or	<30	cigarettes/month,	1-10	cigarettes/day,	11-–10	cigarettes/day,	11–19	cigarettes/day,	and	≥20	cigarettes/day.
2.2.2	Alcohol	Cconsumption
Last-year	alcohol	consumption	pattern	was	examined	in	both	CHIWOS	and	CCHS.	A	four-category	comparable	measure	was	created	in	each	survey:	none	(did	not	drink	in	the	past	12	months),	≤1	time/week,	2-–3	times/week,	and	≥4	times/week.
CCHS	measured	the	monthly	pattern	of	binge	drinking	as,	“How	often	in	the	past	12	months	have	you	had	4	or	more	drinks	on	one	occasion?”	with	six	response	categories:	never,	less	than	once	a	month,	once	a	month,	2	to	–3	times	a	month,	once	a
week,	and	more	than	once	a	week.	The	same	question	but	in	the	last	month	was	measured	in	CHIWOS,	with	an	open-ended	response	option	indicating	the	number	of	times.	Binge	drinking	was	compared	between	the	two	surveys	under	the	assumption	that
past-year	binge	drinking	patterns	were	consistent	with	past	month.	We	created	a	measure	with	similar	response	categories:	no	alcohol	consumed,	alcohol	consumed	but	no	binge	drinking,	binge	drinking	less	than	once	a	week	(i.e.,	equivalently,	less	than	3
times	a	month),	and	binge	drinking	at	least	once	a	week	(i.e.,	equivalently,	four	times	or	more	a	month).	In	CHIWOS,	33	women	reported	last-month	binge	drinking	without	specifying	the	number	of	times	over	the	last	month;	therefore,	instead	of	treating
them	as	missing	values,	we	categorized	them	into	“less	than	once	a	week.”
2.2.3	Drug	Uuse
We	compared	the	use	of	the	following	drugs	available	in	the	two	surveys	in	BC:	cannabis,	cocaine	or	crack,	speed	(amphetamine),	and	heroin.	CCHS	asked	respondents,	“Have	you	used	[any	of	these	drugs]	in	the	past	12	months?”,	affirmative
responses	were	further	followed,	“How	often	[did	you	use	any	of	these	drugs	in	the	past	12	months]?”	with	the	following	response	options:	less	than	once/	month,	1	to	–3	times/month,	once/week,	more	than	once/week,	and	every	day.	CHIWOS	measured
cannabis	use	as,	“What	is	your	cannabis	use	history?”	with	the	following	response	categories:	a)	regularly	in	the	last	30	days,	b)	occasionally	in	the	last	30	days,	c)	used	in	the	past	year	but	not	in	the	past	30	days,	d)	used	in	the	past	but	not	in	the	past	year,
e)	never	used	or	only	ever	used	it	once	or	twice.	To	be	consistent	with	CCHS,	CHIWOS’s	response	options	‘b’	and	‘c’	were	considered	as	occasional	cannabis	use.	CHIWOS	participants	with	a	positive	history	of	cannabis	use	were	also	followed,	“Have	you
used	cannabis	mainly	 for	medicinal	 reasons	or	 recreational	 reasons,	or	both?”	We	 re-coded	medicinal	 (prescribed)	use	of	 cannabis	use	as	non-recreational	use,	while	any	other	 recreational	 reasons	 (alone	or	 in	 combination	with	medicinal	use)	were
considered	as	non-prescribed	cannabis	use.	This	distinction	was	made	as	CCHS	aimed	to	measure	the	use	of	illicit	drugs,	but	not	prescription	drugs.
CHIWOS	assessed	the	use	of	crack	or	cocaine,	speed,	and	heroin	over	the	last	3	months.	Positive	responses	were	additionally	followed	to	measure	the	frequency	of	use	as,	daily,	at	least	once/week,	and	less	than	once/week.	The	same	information
was	assessed	in	CCHS,	but	over	the	past	year.	Crack	and	cocaine	use	were	measured	in	one	single	question	in	CCHS,	while	CHIWOS	measured	them	separately.	Therefore,	daily	use	of	any	of	these	two	drugs	was	considered	as	daily	crack	or	cocaine	use.
For	comparison,	we	created	a	three-category	measure	for	cannabis	use	and	crack	or	cocaine	use	as:	none	(i.e.,	former	or	never),	occasional	(<	once/week),	and	regular	use	(≥	once/week).	As	the	absolute	“n”	for	speed	(amphetamine)	and	heroin
use	did	not	meet	the	minimum	CCHS	vetting	guideline,	we	combined	regular	and	occasional	use	and	then	created	a	binary	variable	for	each	of	these	two	drugs:	none	vs.	occasional/regular	use.
2.3	Data	Aanalysis
We	reported	the	prevalence	and	the	95%	confidence	intervals	(CI)	of	each	substance	from	the	CHIWOS	sample.	We	then	obtained	the	prevalence	of	the	same	substances	from	the	CCHS	sample,	using	sampling	weights	that
Statistics	Canada	assigned	each	respondent	to	correspond	to	the	number	of	Canadian	residents	they	represent.	The	bootstrap	variance	estimation	technique	using	a	set	of	500	replicates	was	used	to	obtain	the	95%	CI	of	the	CCHS
estimates	(Rust	and	Rao,	1996).	To	address	the	imbalanced	distribution	of	age	and	ethnoracial	groups,	we	used	a	standardization	method	which	combines	stratum-specific	prevalence	into	a	single	summary	estimate	through	taking	a
weighted	average	(Rothman	et	al.,	2008).	Standardization	obtains	these	weights	in	averaging	from	a	standard	population.	In	the	present	study,	these	weights	were	obtained	from	the	CHIWOS	dataset	and	applied	to	CCHS	data.	To	do	this,
we	created	a	16-category	variable	representing	CHIWOS’s	age	and	ethnoracial	group	distribution	(i.e.,	four	age	categories:	16-35,	36-45,	46-–35,	36–45,	46–55,	or	>55;	four	ethnoracial	categories:	white,	African,	Caribbean,	Black	(ACB),
Indigenous,	or	other/multi-ethnicities).	We	then	applied	CHIWOS’s	age	and	ethnoracial	group	distribution	to	CCHS	in	order	to	produce	a	second	set	of	estimates	in	which	CCHS	and	CHIWOS	samples	had	a	similar	distribution	with
respect	to	these	two	variables.
The	standardized	prevalence	differences	(SPD)	were	reported	to	quantify	the	differences	between	the	two	surveys	for	each	substance	use.	The	SPD	is	a	commonly	used	measure	for	the	purpose	of	population	health	assessment
and	provides	information	on	the	public	health	impact.	The	SPD	was	computed	by	subtracting	the	CCHS	expected	estimates	standardized	to	age	and	ethnoracial	groups	from	the	CHIWOS	observed	estimates;	with	an	SPD	greater	than
zero	 (i.e.,	 the	null)	denoting	a	greater	prevalence	of	 the	given	substance	 in	WLWH.	The	SPD’s	95%	CI	was	provided	using	 the	methods	of	 variance	estimates	 recovery	 (MOVER)	 (Zou	and	Donner,	 2008	 ),	with	95%	CI	 excluding	0
indicating	statistical	significance	at	p < 0.05.	The	analyses	were	performed	using	Stata	version	15.
3	Results
3.1	Demographics
WLWH	differed	 from	 the	unstandardized	general	 population	data	by	age	and	ethnoracial	 groups	as	well	 as	 relationship	 status,	 education	and	yearly	personal	 income	 levels	 (Table	1).	Greater	proportions	 of	women	 in	 the
unstandardized	general	population	were	older	and	belonged	to	the	white	ethnoracial	group	than	WLWH.	Other	characteristics	of	these	two	samples	are	presented	in	Table	1,	along	with	the	prevalence	in	the	standardized	CCHS	data.
After	standardization,	the	CCHS	estimates	had	identical	age	and	ethnoracial	group	structure.	All	subsequent	comparisons	of	substance	use	were	conducted	using	standardized	data.
Table	1	The	distribution	of	age,	ethno-racial	groups,	relationship	status,	education	status,	and	yearly	personal	income	in	the	cohort	of	women	with	HIV	compared	with	the	assumed	HIV-negative	women	of	the	general
population	in	Canada.
alt-text:	Table	1
CHIWOS	estimates	(N = 1422) CCHS	estimates	(N = 46,851)a
N %	(95%	CI) N Unstandardized
%	(95%	CI)
Standardized
%	(95%	CI)d
Ethno-racial	and	age	groups
White
	16-–35	(years) 145 10.2	(8.7,	11.9) 8,749 21.1	(20.6,	21.7) 10.2e
	36-–45 162 11.4	(9.8,	13.2) 4,582 11.2	(10.6,	11.5) 11.4
	46-–55 178 12.5	(10.9,	14.3) 5,775 13.9	(13.4,	14.5) 12.5
	>	55 99 7.0	(5.7,	8.4) 12,020 29.0	(28.5,	29.6) 7.0
Black
	16-351077.5	(6.3,	9.0)4571.1	(0.9,	1.3)7.5	36-–35 107 7.5	(6.3,	9.0) 457 1.1	(0.9,	1.3) 7.5
	36–45 163 11.5	(9.9,	13.2) 280 0.7	(0.5,	0.9) 11.5
	46-–55 111 7.8	(6.5,	9.3) 333 0.8	(0.6,	1.1) 7.8
	>	55 37 2.6	(1.9,	3.6) 268 0.7	(0.5,	0.8) 2.6
Indigenous
	16-–35 100 7.0	(5.8,	8.5) 424 1.0	(0.9,	1.2) 7.0
	36-–55 120 8.4	(7.1,	10.0) 161 0.4	(0.3,	0.5) 8.4
	36-–45 74 5.2	(4.2,	6.5) 176 0.4	(0.3,	0.5) 5.2
	46-–55 24 1.7	(1.1,	2.5) 255 0.6	(0.5,	0.7) 1.7
Others
16-	16–35 20 1.4	(0.9,	2.2) 3,286 7.9	(7.4,	8.4) 1.4
	36-–45 34 2.4	(1.7,	3.3) 1,837 4.4	(4.0,	4.9) 2.4
	46-–55 37 2.6	(1.9,	3.6) 1,271 3.1	(2.7,	3.5) 2.6
	>	55 11 0.8	(0.4,	1.4) 1,539 3.7	(3.4,	4.1) 0.8
Relationship	status
	Single 689 48.7	(46.1,	51.3) 10,438 24.3	(23.7,	24.8) 26.6	(24.6,	28.7)
	Married,	common-law 545 32.1	(29.7,	34.6) 24,971 58.0	(57.3,	58.7) 55.3	(52.7,	57.9)
	Separated/divorced/widowed 271 19.2	(17.2,	21.3) 7,636 17.7	(17.2,	18.3) 18.1	(15.8,	20.4)
Education	status
	Less	than	high	school 227 16.1	(14.2,	18.1) 6,568 15.4	(14.9,	16.0) 12.3	(11.0,	13.6)
	High	school	completed 532 37.6	(35.1,	40.2) 10,514 24.7	(24.0,	25.4) 23.9	(21.9,	25.9)
	Diploma/trade/college 456 32.2	(29.8,	34.7) 12,998 30.6	(29.8,	31.3) 35.9	(33.4,	38.4)
	University	degree	(≥Bachelor’s	degree) 200 14.1	(12.4,	16.1) 12,474 29.3	(28.6,	30.1) 27.9	(25.4,	30.4)
Yearly	personal	incomeb
	<20,000	CADc 997 70.3	(67.8,	72.6) 12,263 29.1	(28.4,	29.9) 28.1	(26.1,	30.0)
	20,000	to	<40,000	CAD 244 17.2	(15.3,	19.3) 10,425 24.8	(24.1,	25.5) 24.5	(22.4,	26.7)
	≥	40,000	CAD 144 10.1	(8.7,	11.8) 12,620 30.0	(29.2,	30.8) 33.1	(30.4,	35.8)
	Not	stated 34 2.4	(1.7,	3.3) 6,795 16.1	(15.5,	16.8) 14.3	(12.3,	16.3)
Trans	women 54 3.8	(2.9,	4.9) ---	f ---f ---f
aOut	of	128,310	respondents,	46,851	(36.5%)	were	eligible	for	the	current	study:	women	aged	16+	residing	in	three	provinces	of	BC,	ON,	QC.
b Aged	>	17	years	old.
c Canadian	dollar	(CAD).
d 95%	CIs	were	not	estimated	for	standardization	variables.
e Standardization	made	the	two	study	populations	identical	with	regard	to	age	and	ethno-racial	group	structure.
fNot	available	as	CCHS	does	not	contain	data	identifying	trans	status.
Overall	83%	and	87%	of	WLWH	reported	taking	HIV	medication	and	having	a	suppressed	viral	load	(i.e.,	<50	 c/mL),	respectively.	The	median	time	living	with	HIV	since	diagnosis	was	11	years	(IQR:	7,	17)	(data	not	shown).
3.2	Cigarette	smoking	(Table	2)
A	higher	prevalence	of	cigarette	smoking	frequency	and	intensity	was	reported	among	WLWH	compared	with	estimates	expected	based	on	the	age-/ethnoracial-standardized	women	of	the	general	population.	Current	cigarette
smoking	(i.e.,	daily/occasional)	was	reported	by	43.7%	of	WLWH	relative	to	17.8%	of	the	expected	estimates	of	general	population	(SPD	25.9%),	indicating	that	25.9%	(i.e.,	259	per	1000)	of	WLWH	reported	current	cigarette	smoking,
in	excess	of	what	would	be	expected	of	Canadian	women	of	similar	ages/ethnoracial	backgrounds.	Daily	cigarette	smoking	was	reported	by	40.7%	of	WLWH	versus	13.9%	of	expected	estimates	from	general	population	women	(SPD
26.8%).	WLWH	tended	to	smoke	a	cigarette	more	intensely	than	the	expected	estimates	of	the	general	population.
Table	2	Comparison	of	cigarette	smoking	between	women	with	HIV	(N = 1422)	and	assumed	HIV-negative	women	of	the	general	population	(N = 46,851).
alt-text:	Table	2
Cigarette	smoking	measures CHIWOS CCHS	estimates SPDd
CCHSb AER	Std.c
Overall	cigarette	smoking
Non-smoker	(i.e.,	former/never) 56.3
(53.7,	58.9)a
84.3
(83.7,	84.9)
82.2
(80.8,	83.7)
-25.9(-28.9,	-−25.9
(−28.9,	−22.9)
Current	smokers	(i.e.,	daily/occasional) 43.7
(41.1,	46.3)
15.7
(15.1,	16.3)
17.8
(16.3,	19.2)
25.9
(22.9,	28.9)
Current	cigarette	smoking	status
Non-smoker	(i.e.,	former/never) 57.0
(54.4,	59.6)
84.3
(83.7,	84.9)
82.2
(80.8,	83.7)
-25.2(-28.2,	-−25.2
(−28.2,	−22.2)
Occasional	smokerse 2.3
(1.6,	3.2)
3.8
(3.5,	4.2)
3.9
(3.2,	4.6)
-1.6	(-2.6,	-−1.6	
(−2.6,	−0.5)
Daily	smokersf 40.7
(38.1,	43.3)
11.9
(11.3,	12.4)
13.9
(12.5,	15.2)
26.8
(23.9,	29.7)
Intensity	of	cigarette	smoking
Non-smoker	(i.e.,	former/never)g 57.0
(54.4,	59.6)
84.4
(83.8,	85.0)
82.4
(80.9,	83.9)
-25.4(-28.4,	-−25.4
(−28.4,	−22.4)
<1	cig/day	or	<30	cig/month 2.3
(1.6,	3.2)
2.5
(2.3,	2.8)
2.5
(2.1,	2.9)
-0.2	(-−0.2	(−1.0,	0.8)
1	to	10	cig/day 20.4
(18.3,	22.6)
6.6
(6.2,	7.0)
7.8
(6.7,	9.0)
12.6
(10.2,	15.1)
>10	to	<20	cig/day 5.4
(4.4,	6.8)
3.2
(2.9,	3.4)
4.0
(3.2,	4.8)
1.4
(0.1,	3.0)
≥	20	cig/day 14.9
(13.1,	16.9)
3.3
(3.0,	3.6)
3.3
(2.8,	3.8)
11.6
(9.8,	13.6)
aData	are	%	(95%	CI).
bUnstandardized	weighted	estimates	are	reported	and	the	95%	CI	was	constructed	using	bootstrap	method.
c Age-	and	ethno-racial-standardized	expected	estimates	based	on	women	of	the	general	population	from	CCHS.
d SPD:	standardized	prevalence	difference	(%	(95%	CI));	the	95%	CI	was	constructed	using	MOVER	algorithm.
eOccasional	smokers	(<1	cigarette/day	or	<30	cigarettes/month).
fDaily	smokers	(≥1	cigarettes/day	or	≥30	cigarettes/month).
g Because	of	missing	values	in	variable	intensity	of	cigarette	smoking,	the	proportion	of	the	first	and	second	categories	if	different	from	the	same	categories	in	variable	current	cigarette	smoking	status,	while	the
absolute	numbers	is	the	same.
3.3	Alcohol	Cconsumption	(Table	3)
WLWH	more	frequently	reported	no	alcohol	consumption	compared	with	the	expected	estimates	(40.7%	vs.	28.0%).	The	proportion	of	alcohol	consumption	categories	among	WLWH	than	expected	estimates	from	standardized
general	population	data	was:	46.8%	vs.	52.2%	consumed	alcohol	≤1	time/week,	7.0%	vs.	12.9%	consumed	alcohol	2-–3	times/week,	and	5.5%	vs.	6.9%	consumed	alcohol	4+	times/week.	The	monthly	pattern	of	binge	drinking	in	WLWH
was:	15.4%	vs.	30.6%	for	less	than	once/week	(SPD	-−15.2%),	and	4.6%	vs.	3.9%	for	at	least	once/week	(SPD	0.7%).	The	combination	of	these	two	categories	showed	that	20.0%	of	WLWH	reported	binge	drinking	at	least	once/month
compared	with	34.5%	in	women	of	the	general	population.
Table	3	Comparison	of	alcohol	consumption	between	women	with	HIV	(N = 1422)	and	assumed	HIV-negative	women	of	the	general	population	(N = 46,851).
alt-text:	Table	3
CHIWOS CCHS	estimates SPDd
CCHSb AER	Std.c
Alcohol	consumption	frequency
None	(Never/none	in	specified	time) 40.7
(38.2,	43.3)a
24.5
(23.7,	25.4)
28.0
(25.4,	30.5)
12.7
(9.1,	1.4)
≤1	time	a	week 46.8
(44.2,	49.4)
51.3
(50.4,	52.1)
52.2
(49.6,	54.8)
-5.4(-9.1,	-1.7)2-−5.4
(−9.1,	−1.7)
2–3	times	a	week 7.0
(5.7,	8.4)
15.1
(14.5,	15.7)
12.9
(11.5,	14.1)
-5.9(-7.7,	-−5.9
(−7.7,	−3.9)
4+	times	a	week 5.5
(4.4,	6.8)
9.1
(8.7,	9.5)
6.9
(5.8,	8.1)
-−1.4
(-3.0,	0.4)
Binge	drinking	categoriese
No	alcohol	consumed 41.0
(38.5,	43.7)
24.6
(23.8,	25.5)
28.0
(25.4,	30.6)
13.0
(9.4,	16.7)
Alcohol	consumed,	not	binge 39.0
(36.4,	41.5)
40.3
(39.5,	41.1)
37.5
(34.9,	40.0)
1.5
(-−2.1,	5.1)
Binge	drinking	less	than	once	a	week 15.4
(13.6,	17.4)
30.9
(30.1,	31.7)
30.6
(28.7,	32.4)
-15.2(-17.8,	-−15.2
(−17.8,	−12.6)
Binge	drinking	at	least	once	a	week 4.6
(3.6,	5.9)
4.2
(3.9,	4.5)
3.9
(3.3,	4.4)
0.7
(-−0.3,	2.1)
aData	are	%	(95%	CI).
bUnstandardized	weighted	estimates	are	reported	and	the	95%	CI	was	constructed	using	bootstrap	method.
c Age-	and	ethno-racial-standardized	expected	estimates	based	on	women	od	the	general	population	from	CCHS.
d SPD:	standardized	prevalence	difference	(%	(95%	CI)),	and	the	95%	CI	was	constructed	using	MOVER	algorithm.
e CHIWOS	measured	the	last-month	pattern	of	binge	drinking,	while	CCHS	measured	the	last-year	pattern	of	binge	drinking.
3.4	Drug	Uuse	(Table	4)
Last-month	non-prescribed	cannabis	use	in	WLWH	from	BC	was	almost	two	times	greater	than	the	last-year	use	of	this	drug	from	women	of	the	general	population	in	BC:	14.6%	vs.	6.6%	reported	regular	use	(SPD	8.0%),	and
18.1%	vs.	6.1%	reported	occasional	use	(SPD	12.0%).	The	results	of	last	3	months	use	of	illicit	drug	use	compared	with	last-year	use	of	these	drugs	showed	a	higher	proportion	of	WLWH	in	BC	reported	cocaine	or	crack	use:	16.8%	vs.
0.1%	for	regular	use	(SPD	16.7%),	and	8.2%	vs.	1.5%	for	occasional	use	(SPD	6.7%),	regular/occasional	speed	use	(2.5%	vs.	0.1%;	SPD	2.4%),	and	regular/occasional	heroin	use	(11.3%	vs.	0.1%;	SPD	11.2%).
Table	4	Comparing	illicit	drug	use	between	women	living	with	HIV	and	assumed	HIV-negative	women	of	the	general	populationa.
alt-text:	Table	4
Drug	useg CHIWOS CCHS	estimates SPDe
CCHSc AER	Std.d
Non-prescribed	cannabis	useh
Regular	usei 14.6
(11.3,	18.7)b
4.5
(3.4,	5.2)
6.6
(4.7,	8.6)
8.0
(4.1,	8.6)
Occasional	usej 18.1
(14.4,	22.4)
7.1
(6.1,	8.1)
6.1
(4.9,	7.2)
12.0
(8.1,	16.5)
Nonek 67.3
(62.2,	72.1)
88.4
(87.2,	89.6)
87.3
(83.5,	91.1)
-20.0(-26.3,	-−20.0
(−26.3,	−13.9)
Cocaine	or	crack	use
Regular	usel 16.8
(13.2,	21.0)
0.1
(0.01,	0.2)
0.1
(0.00,	0.2)
16.7
(13.1,	20.9)
Occasional	usem 8.2
(5.78,	11.61)
0.7
(0.4,	1.0)
1.5
(0.2,	2.9)
6.7
(3.9,	10.3)
None	(never	or	former) 75.0
(70.2,	79.2)
99.2
(98.8,	99.5)
98.4
(95.0,	101.7)
-23.4(-29.2,	-−23.4
(−29.2,	−17.9)
Speed	(amphetamine)	use
Regular/occasional	usel,m,n 2.5
(1.3,	4.8)
0.1
(0.01,	0.2)
0.1
(0.00,	0.2)
2.4
(1.2,	4.7)
None	(never	or	former) 97.5
(95.2,	98.68)
99.9
(99.8,	100.0)
99.9
(96.8,	100.0)	††-2.4(-f
−2.4
(−6.2,	0.9)
Heroin	use
Regular/occasional	usel,m,n 11.3
(8.4,	15.1)
0.1
(0.02,	0.2)
0.1
(0.01,	0.2)
11.2
(8.3,	15.0)
None	(never	or	former) 88.7
(84.9,	91.6)
99.9
(99.7,	100.0)
99.9
(96.8,	100.0)f
-11.2(-16.1,	-−11.2
(−16.1,	−7.0)
a CHIWOS-BC	(N = 356)	and	CCHS-BC	(N = 7698).
bData	are	%	(95%	CI).
cUnstandardized	weighted	estimates	are	reported	and	the	95%	CI	was	constructed	using	bootstrap	method.
d Age-	and	ethno-racial-standardized	expected	estimates	based	on	women	of	the	general	population	from	CCHS.
e SPD:	standardized	prevalence	difference	(%	(95%	CI)),	and	the	95%	CI	was	constructed	using	MOVER	algorithm.
f The	upper	limit	was	102.96%	but	we	made	is	to	the	maximum	proportion	100.0%.
g CCHS	collected	data	for	the	period	of	last	12	months	for	all	drugs,	while	CHIWOS	collected	data	on	cannabis	use	for	last	month	and	other	drugs	in	last	three	months.
h Any	non-prescribed	use	of	cannabis	(i.e.,	non-medicinal,	non-prescribed,	self-medicating,	or	both	medicinal	and	non-medicinal	use	simultaneously).
i CCHS:	every	day	or	at	least	once	a	week,	while	it	was	measured	as	using	regularly	in	CHIWOS.
j CCHS:	Occasional	use	(1-–3	times	a	month	or	less	than	once	a	month),	CHIWOS:	occasional	use	(occasionally	or	used	but	not	in	the	past	30	days).
kNo	non-prescribed	or	medicinal	cannabis	use.
l Regular	use:	at	least	once	a	week.
mOccasional/episodic:	less	than	once	a	week.
n Regular	and	occasional	use	were	merged	in	Amphetamine	and	Heroin	use	as	the	absolute	“n”	did	not	meet	the	minimum	vetting	guideline.
4	Discussion
We	 found	 that	 a	 considerable	 proportion	 of	WLWH	 reported	 current	 cigarette	 smoking,	 were	 intensive	 cigarette	 smokers	 (i.e.,	 ≥20	 cigarettes/day),	 reported	 binge	 drinking,	 and	 reported	 regular/occasional	 use	 of	 non-
prescribed	cannabis,	and	other	illicit	drugs	including	crack	or	cocaine,	speed,	and	heroin.	We	also	provided	evidence	for	an	excess	prevalence	of	cigarette	smoking	and	the	use	of	non-prescribed	cannabis,	and	other	illicit	drugs,	but	a
lower	to	similar	frequency	of	alcohol	consumption,	in	WLWH	compared	to	their	age-	and	ethnoracial	group-similar	general	population	counterparts.
While	a	considerable	difference	was	found	between	WLWH	and	their	general	population	counterparts	with	regard	to	drug	use	and	cigarette	smoking,	but	not	hazardous	alcohol	drinking,	we	acknowledge	that	these	differences
could	 in	 part	 be	 because	 of	 other	 uncontrolled	 population	 background	 characteristics.	 For	 example,	 prior	 studies	 have	 highlighted	 the	 contribution	 of	 socioeconomic	 factors	 (e.g.,	 low	 income,	 unemployment)	 and	mental	 health
conditions	to	substance	among	WLWH	(Cook	et	al.,	2009).	Moreover,	HIV-specific	factors	such	as	HIV-related	stigma	may	play	a	role	in	substance	use	as	a	maladaptive	or	avoidant	coping	strategy	(Turan	et	al.,	2017).	However,	control
of	 these	 in	cross-sectional	analysis	 can	be	problematic	 in	 ignoring	potential	mediation	and	creating	artificially	 similar	groups	 that	obscure	 real	differences	 that	 can	 result	 from	age	 (or	 life	 stage)	and	systemic	discrimination	and
differential	life	options	across	ethnoracial	groups.
Our	findings	were	consistent	with	the	findings	of	the	few	available	studies	comparing	WLWH	with	HIV-negative	women.	A	higher	proportion	of	cigarette	smoking	was	found	among	WLWH	in	a	2015	US	study	(34.6%	vs.	18.0%
were	current	 cigarette	 smokers;	with	an	age-ethnoracial-education-poverty	adjusted	prevalence	difference	of	16.6%)	 (Mdodo	et	al.,	2015)	 and	a	2014	French	 study	 (32%	 regular	 tobacco	 smokers,	with	 an	 age-education	 adjusted
prevalence	rate	ratio	of	1.32)	(Tron	et	al.,	2014).	Consistent	with	previous	research	(Ikeda	et	al.,	2016),	alcohol	consumption	was	comparatively	lower	in	WLWH	than	that	in	the	general	population;	however,	it	was	still	one	of	the	most
prevalent	substances	reported	by	WLWH	in	the	current	study.	The	reason	for	the	observed	lower	frequency	of	alcohol	consumption	among	WLWH	of	the	current	study	is	unclear.	Further	research	is	needed	to	explore	whether	such
lower	frequency	of	alcohol	use	among	WLWH	is	due	to	the	higher	use	of	other	drugs	such	as	recreational	cannabis	use.	Given	the	negative	impacts	of	alcohol	consumption	on	care	and	treatment	outcomes	(Zhang	et	al.,	2018),	our
findings	in	line	with	other	studies	of	women	with	HIV	(Jones	et	al.,	2010)	suggest	that	there	is	a	need	for	screening	of	alcohol	drinking	and	targeted	interventions	within	HIV	care.
The	comparison	of	our	findings	on	illicit	drug	use	with	extant	literature	is	difficult	because	there	are	few	such	comparison	analyses	specifically	for	WLWH.	However,	identifying	a	higher	prevalence	of	drug	use	in	individuals
with	HIV	than	the	general	population	is	relevant	to	the	HIV	setting,	and	suggests	the	need	to	ensure	that	factors	that	affect	substance	use	among	WLWH	are	identified	and	addressed	and	that	adequate	resources	are	provided	for
addressing	drug	use	in	the	context	of	HIV	care.	Limited	descriptive	studies	have	also	indicated	high	prevalence	of	substance	use	in	WLWH;	for	example,	current	cigarette	smoking	(56%)	and	concomitant	use	of	other	drugs	in	smokers
(24%	vs.	4%	in	nonsmokers)	(Feldman	et	al.,	2006),	past-year	hazardous	drinking	over	an	11-year	follow-up	period	(ranged	from	14%	to	24%)	(Cook	et	al.,	2009),	current	marijuana	use	(from	21%	to	14%	over	the	16-year	follow-up
period)	and	daily	marijuana	use	(from	3.3%	to	6.1%	in	all	studied	women)	(D’Souza	et	al.,	2012).	Future	research	could	examine	which	factors	may	contribute	to	WLWH	using	or	avoiding	substances,	including	discrimination,	HIV-
related	stigma,	intimate	partner	violence,	and	other	factors	that	can	lead	to	initiation	or	continuation	of	substance	use.	The	identified	substance	use	disparities,	particularly	smoking	and	illicit	drug	use,	can	help	researchers	explore
pathways	leading	to	greater	vulnerability	among	WLWH.
Given	the	contribution	of	substance	use	to	suboptimal	HIV	outcomes,	considering	the	mixed	evidence	for	the	role	of	cannabis	(Bonn-Miller	et	al.,	2014;	Okafor	et	al.,	2017),	the	high	substance	use	prevalence	identified	in	the
current	research	has	important	implications	for	the	clinical	management	of	HIV	(Cook	et	al.,	2008;	Feldman	et	al.,	2006).	This	is	particularly	important	as	substance	use	frequently	co-presents	with	other	health-related	problems	such
as	psychiatric	comorbidities	and	socio-structural	barriers,	that	interactively	impact	HIV	outcomes	in	individuals	with	HIV	including	WLWH	(Cook	et	al.,	2007;	Krusi	et	al.,	2010;	Nahvi	and	Cooperman,	2009).	These	findings	highlight
the	need	to	make	interventions	available	to	women	who	use	both	drugs	and	antiretroviral	therapy,	particularly	in	cases	where	the	substance	use	interferes	with	maintenance	of	effective	HIV	treatment	(Sharpe	et	al.,	2004;	Zhang	et	al.,
2018).	Integration	of	substance	use	treatment	services	into	HIV	primary	care	settings	may	contribute	to	enhancing	the	quality	of	HIV	care	and	care	delivery	(Altice	et	al.,	2011;	Cook	et	al.,	2008;	Malta	et	al.,	2008).	Our	findings	also
advocate	for	tailored,	women-centered	harm	reduction	strategies	in	which	women’s	unique	needs	are	effectively	recognized	(O’Brien	et	al.,	2017),	and	peer-driven	interventions	through	which	peers	can	also	contribute	to	the	care	and
treatment	programs	delivery	(Simoni	et	al.,	2011).	Having	access	 to	pharmacologic	and	psychotropic	 substance	use	and	harm	reduction	services	 through	 this	model	of	 care	 is	essential	 to	 reduce	use	and	harms	of	 substance	use
(Durvasula	and	Miller,	2014;	Gonzalez	et	al.,	2011;	Malta	et	al.,	2008).	To	improve	greater	involvement	and	adherence	to	treatment,	one	recommendation	is	that	such	a	model	of	care	delivery	also	provides	sustained	follow-up	with
regular	evaluations	of	HIV	therapies	to	substance-using	WLWH	(Cohen	et	al.,	2004;	Cook	et	al.,	2008;	Sharpe	et	al.,	2004).
This	study	had	some	limitations.	CHIWOS	recruited	WLWH	through	Peer	Research	Associates	(PRAs)	–	a	non-random	sampling	design.	Additionally,	self-report	data	on	substance	use,	a	potentially	stigmatizing	behavior,	 is
subject	to	social	desirability	bias;	however,	this	concern	might	have	been	mitigated	in	CHIWOS	by	using	the	PRAs,	who	also	shared	the	experience	of	living	with	HIV.	This	was	an	attempt	to	build	trust	with	WLWH,	to	allow	for	them	to
better	contribute	to	the	research	in	sharing	their	sensitive	information	(Webster	et	al.,	2018).	Moreover,	we	compared	the	measure	of	substance	use	in	WLWH	with	the	assumed	HIV-negative	women	of	the	general	population.	Because
of	 small	 population	 estimates	 of	WLWH	 in	 Canada	 –	 97	 per	 100,000	 females	 (Public	Health	 Agency	 of	 Canada,	 2015),	 the	 inclusion	 of	WLWH	 in	 the	 assumed	HIV-negative	 group	would	 not	 substantially	 change	 our	 estimates.
Furthermore,	while	CHIWOS	collected	data	on	cisgender	(non-trans)	women	and	trans	women	with	HIV,	CCHS	does	not	contain	data	identifying	trans	women;	therefore,	it	is	both	likely	that	there	are	also	trans	women	in	CCHS	and	it
is	impossible	to	adjust	for	gender	identity.
In	conclusion,	substance	use	was	prevalent	among	women	living	with	HIV,	with	prevalence	of	cigarette	smoking	and	illicit	drug	use	in	excess	of	what	would	be	expected,	but	not	of	alcohol	consumption	and	binge	drinking.	Due
to	their	negative	impacts	on	HIV	outcomes,	morbidity,	and	mortality,	these	results	highlight	the	need	for	future	research	and	programming	to	better	understand	factors	that	may	contribute	to	substance	use	within	the	group	of	WLWH,
and	to	intervene	on	these	factors,	or	on	health	risk	factors	within	HIV	care	settings.	Future	research	may	also	be	useful	in	identifying	substance	users	through	screening	methods,	in	educating	HIV	care	providers	concerning	screening
for	substance	use	problems,	and	in	addressing	specific	causal	pathways	for	the	use	of	substances	and	their	impacts	on	HIV	outcomes.
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Highlights
• Women	with	HIV	(WLWH)	were	26.8%	excess	daily	smokers	vs.	general	population	women.
• WLWH	were	8.0%	excess	regular	cannabis	users	vs.	general	population	women.
• WLWH	were	16.7%	excess	regular	crack/cocaine	users	vs.	general	population	women.
Queries	and	Answers
Query:	Please	check	the	presentation	of	‘Tables	1-4’,	and	correct	if	necessary.
Answer:	The	presentation	of	the	tables	is	correct
Query:	Your	article	is	registered	as	a	regular	item	and	is	being	processed	for	inclusion	in	a	regular	issue	of	the	journal.	If	this	is	NOT	correct	and	your	article	belongs	to	a	Special	Issue/Collection	please
contact	s.hubbard@elsevier.com	immediately	prior	to	returning	your	corrections.
Answer:	Correct,	this	article	is	registered	as	a	regular	item	and	regular	issue	of	the	journal.	
Query:	The	author	names	have	been	tagged	as	given	names	and	surnames	(surnames	are	highlighted	in	teal	color).	Please	confirm	if	they	have	been	identified	correctly.
Answer:	Yes
Query:	Please	note	that	the	significance	of	footnote	’#’	link	to	the	’On	Behalf	of	the	CHIWOS	Research	Team’	has	not	been	provided.	Therefore	it	has	been	removed.	Please	check	and	correct	if
necessary.
Answer:	Please	see	the	attached	file.	We	provided	(in	the	initial	submission)	the	list	of	the	names	of	our	survey	research	team.	The	sign	"#"	refers	to	the	list	that	is	now	attached.	
Attachments:	CHIWOS	research	team.docx
Query:	Please	check	the	presentation	of	all	affiliations,	and	correct	if	necessary.
Answer:	They	are	correct.	
Query:	One	or	more	sponsor	names	and	the	sponsor	country	identifier	may	have	been	edited	to	a	standard	format	that	enables	better	searching	and	identification	of	your	article.	Please	check	and
correct	if	necessary.
Answer:	Yes
Query:	Uncited	reference:	This	section	comprises	reference	that	occur	in	the	reference	list	but	not	in	the	body	of	the	text.	Please	position	the	reference	in	the	text	or,	alternatively,	delete	it.	Any
reference	not	dealt	with	will	be	retained	in	this	section.
Answer:	This	reference	refers	to	this	section	of	the	introduction	(first	paragraph	in	the	Introduction):	"...	despite	the	substantial	advances	obtained	from	combination	antiretroviral	therapy	(cART),	e.g.,
improved	life	expectancy	in	PLWH	(2008)."	We	only	have	the	"2008"	in	the	body	of	the	text	not	the	list	of	the	authors	of	this	reference.	The	reason	is	that	there	is	no	list	of	co-authors	for	this
publication/reference.	The	suggestion	is	this:	A)	Please	add	this	"Antiretroviral	Therapy	Cohort	Collaboration"	to	the	first	paragraph	of	the	Introduction	in	the	corresponding	section	(specified)	and
change	it	as,	"...	despite	the	substantial	advances	obtained	from	combination	antiretroviral	therapy	(cART),	e.g.,	improved	life	expectancy	in	PLWH	(Antiretroviral	Therapy	Cohort	Collaboration,
2008)."	Then,	B)	please	revise	this	reference	in	the	reference	list	as,	Antiretroviral	Therapy	Cohort	Collaboration,	2008.	Life	expectancy	of	individuals	on	combination	antiretroviral	therapy	in	high-
income	countries:	a	collaborative	analysis	of	14	cohort	studies.	Lancet	372,	293-299.
• WLWH	were	11.2%	excess	regular	heroin	users	vs.	general	population	women.
• Alcohol	use	was	either	similar	or	lower	in	WLWH	vs.	general	population	women.
